Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence
There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor c...
Main Authors: | Cathrin Rohleder, Juliane K. Mueller, Bettina Lange, F. Markus Leweke |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00422/full |
Similar Items
-
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
by: Albert Batalla, et al.
Published: (2019-07-01) -
The Impact of THC and CBD in Schizophrenia: A Systematic Review
by: Saeed Ahmed, et al.
Published: (2021-07-01) -
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers
by: Timo Woelfl, et al.
Published: (2020-11-01) -
Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
by: Christopher S. Pauli, et al.
Published: (2020-02-01) -
Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia
by: Jan van Amsterdam, et al.
Published: (2018-09-01)